Clinical Trial Update: Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC [NA]

View source ↗

Summary

This clinical trial update describes an early feasibility study evaluating YntraDose as a neoadjuvant treatment for locally advanced, unresectable pancreatic du…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• YntraDose

Snippet

Sponsor: BetaGlue Therapeutics SpA | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced | NA | Status: RECRUITING